Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers

Neoplastic growth and dissemination involve increased proteolytic activity that is able to escape the regulative elements. Matrix metalloproteinases (MMPs), particularly gelatinases A and B (MMP-2 and -9), play a role in tumor invasion and angiogenesis, and they participate in cancer progression in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochimie 2005-03, Vol.87 (3), p.287-297
1. Verfasser: Turpeenniemi-Hujanen, T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 297
container_issue 3
container_start_page 287
container_title Biochimie
container_volume 87
creator Turpeenniemi-Hujanen, T.
description Neoplastic growth and dissemination involve increased proteolytic activity that is able to escape the regulative elements. Matrix metalloproteinases (MMPs), particularly gelatinases A and B (MMP-2 and -9), play a role in tumor invasion and angiogenesis, and they participate in cancer progression in several neoplasias. The expression of tissue inhibitors of gelatinases, TIMPs-1 and -2, has also been shown to be associated with the clinical course in some cancers. The prognostic value of these markers, however, seems to vary a great deal in different neoplastic diseases. In this review, the impact of the gelatinases and their inhibitors on the clinical course in several solid cancers is evaluated based on the growing data from recent clinical studies. The clinical data most often explore the overexpression of mRNA or immunoreactive protein in tumor tissue, or measure the concentration of the circulating proteinase or its inhibitor in pretreatment or follow-up serum samples. The growing amount of recent clinical data suggests that the impact of gelatinases on treatment decisions should be tested in clinical trials.
doi_str_mv 10.1016/j.biochi.2005.01.014
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67532149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0300908405000295</els_id><sourcerecordid>67532149</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-d752ca2f89429b7a3522cf0420e9ed10040d29b24dd897fd527671d29e40f3e3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotn78A5GcRA9bJx_7dRFEtAqKHryHNJm1U7a7NdkK_ntTW_AmDAzkfWaSPIydCZgIEMX1YjKj3s1pIgHyCYhUeo-NRaGqrBCV2mdjUABZDZUesaMYF5BAkPUhG4m8rIQS-ZjZKbZ2oM5GjPzy5eUtk9x2nmf11W8f5kiBd3ZYB9ty6uY0o6EPkdvIV6H_6Po4kEuBJ2d_A-p47Fvy3NnOYYgn7KCxbcTTXT9m7w_373eP2fPr9Onu9jlzqoAh82UunZVNVWtZz0qrcildA1oC1ugFgAafAqm9r-qy8bksi1KkI9TQKFTH7GK7Nr3qc41xMEuKDtvWdtivoynKXEmh6wTqLehCH2PAxqwCLW34NgLMxqxZmK1ZszFrQKTSaex8t389W6L_G9qpTMDNFsD0yS_CYKIjTAo8BXSD8T39f8MPmumKqg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67532149</pqid></control><display><type>article</type><title>Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Turpeenniemi-Hujanen, T.</creator><creatorcontrib>Turpeenniemi-Hujanen, T.</creatorcontrib><description>Neoplastic growth and dissemination involve increased proteolytic activity that is able to escape the regulative elements. Matrix metalloproteinases (MMPs), particularly gelatinases A and B (MMP-2 and -9), play a role in tumor invasion and angiogenesis, and they participate in cancer progression in several neoplasias. The expression of tissue inhibitors of gelatinases, TIMPs-1 and -2, has also been shown to be associated with the clinical course in some cancers. The prognostic value of these markers, however, seems to vary a great deal in different neoplastic diseases. In this review, the impact of the gelatinases and their inhibitors on the clinical course in several solid cancers is evaluated based on the growing data from recent clinical studies. The clinical data most often explore the overexpression of mRNA or immunoreactive protein in tumor tissue, or measure the concentration of the circulating proteinase or its inhibitor in pretreatment or follow-up serum samples. The growing amount of recent clinical data suggests that the impact of gelatinases on treatment decisions should be tested in clinical trials.</description><identifier>ISSN: 0300-9084</identifier><identifier>EISSN: 1638-6183</identifier><identifier>DOI: 10.1016/j.biochi.2005.01.014</identifier><identifier>PMID: 15781315</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Clinical Trials as Topic ; Disease Progression ; Enzyme Inhibitors - therapeutic use ; Gene Expression Regulation, Neoplastic ; Genetic Markers - drug effects ; Humans ; Matrix Metalloproteinase Inhibitors ; Neoplasm Metastasis ; Neoplasms - classification ; Neoplasms - drug therapy ; Neoplasms - enzymology ; Prognosis</subject><ispartof>Biochimie, 2005-03, Vol.87 (3), p.287-297</ispartof><rights>2005 Elsevier SAS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-d752ca2f89429b7a3522cf0420e9ed10040d29b24dd897fd527671d29e40f3e3</citedby><cites>FETCH-LOGICAL-c360t-d752ca2f89429b7a3522cf0420e9ed10040d29b24dd897fd527671d29e40f3e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biochi.2005.01.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15781315$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turpeenniemi-Hujanen, T.</creatorcontrib><title>Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers</title><title>Biochimie</title><addtitle>Biochimie</addtitle><description>Neoplastic growth and dissemination involve increased proteolytic activity that is able to escape the regulative elements. Matrix metalloproteinases (MMPs), particularly gelatinases A and B (MMP-2 and -9), play a role in tumor invasion and angiogenesis, and they participate in cancer progression in several neoplasias. The expression of tissue inhibitors of gelatinases, TIMPs-1 and -2, has also been shown to be associated with the clinical course in some cancers. The prognostic value of these markers, however, seems to vary a great deal in different neoplastic diseases. In this review, the impact of the gelatinases and their inhibitors on the clinical course in several solid cancers is evaluated based on the growing data from recent clinical studies. The clinical data most often explore the overexpression of mRNA or immunoreactive protein in tumor tissue, or measure the concentration of the circulating proteinase or its inhibitor in pretreatment or follow-up serum samples. The growing amount of recent clinical data suggests that the impact of gelatinases on treatment decisions should be tested in clinical trials.</description><subject>Clinical Trials as Topic</subject><subject>Disease Progression</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genetic Markers - drug effects</subject><subject>Humans</subject><subject>Matrix Metalloproteinase Inhibitors</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasms - classification</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - enzymology</subject><subject>Prognosis</subject><issn>0300-9084</issn><issn>1638-6183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotn78A5GcRA9bJx_7dRFEtAqKHryHNJm1U7a7NdkK_ntTW_AmDAzkfWaSPIydCZgIEMX1YjKj3s1pIgHyCYhUeo-NRaGqrBCV2mdjUABZDZUesaMYF5BAkPUhG4m8rIQS-ZjZKbZ2oM5GjPzy5eUtk9x2nmf11W8f5kiBd3ZYB9ty6uY0o6EPkdvIV6H_6Po4kEuBJ2d_A-p47Fvy3NnOYYgn7KCxbcTTXT9m7w_373eP2fPr9Onu9jlzqoAh82UunZVNVWtZz0qrcildA1oC1ugFgAafAqm9r-qy8bksi1KkI9TQKFTH7GK7Nr3qc41xMEuKDtvWdtivoynKXEmh6wTqLehCH2PAxqwCLW34NgLMxqxZmK1ZszFrQKTSaex8t389W6L_G9qpTMDNFsD0yS_CYKIjTAo8BXSD8T39f8MPmumKqg</recordid><startdate>20050301</startdate><enddate>20050301</enddate><creator>Turpeenniemi-Hujanen, T.</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050301</creationdate><title>Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers</title><author>Turpeenniemi-Hujanen, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-d752ca2f89429b7a3522cf0420e9ed10040d29b24dd897fd527671d29e40f3e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Clinical Trials as Topic</topic><topic>Disease Progression</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genetic Markers - drug effects</topic><topic>Humans</topic><topic>Matrix Metalloproteinase Inhibitors</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasms - classification</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - enzymology</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turpeenniemi-Hujanen, T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochimie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turpeenniemi-Hujanen, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers</atitle><jtitle>Biochimie</jtitle><addtitle>Biochimie</addtitle><date>2005-03-01</date><risdate>2005</risdate><volume>87</volume><issue>3</issue><spage>287</spage><epage>297</epage><pages>287-297</pages><issn>0300-9084</issn><eissn>1638-6183</eissn><abstract>Neoplastic growth and dissemination involve increased proteolytic activity that is able to escape the regulative elements. Matrix metalloproteinases (MMPs), particularly gelatinases A and B (MMP-2 and -9), play a role in tumor invasion and angiogenesis, and they participate in cancer progression in several neoplasias. The expression of tissue inhibitors of gelatinases, TIMPs-1 and -2, has also been shown to be associated with the clinical course in some cancers. The prognostic value of these markers, however, seems to vary a great deal in different neoplastic diseases. In this review, the impact of the gelatinases and their inhibitors on the clinical course in several solid cancers is evaluated based on the growing data from recent clinical studies. The clinical data most often explore the overexpression of mRNA or immunoreactive protein in tumor tissue, or measure the concentration of the circulating proteinase or its inhibitor in pretreatment or follow-up serum samples. The growing amount of recent clinical data suggests that the impact of gelatinases on treatment decisions should be tested in clinical trials.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>15781315</pmid><doi>10.1016/j.biochi.2005.01.014</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-9084
ispartof Biochimie, 2005-03, Vol.87 (3), p.287-297
issn 0300-9084
1638-6183
language eng
recordid cdi_proquest_miscellaneous_67532149
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Clinical Trials as Topic
Disease Progression
Enzyme Inhibitors - therapeutic use
Gene Expression Regulation, Neoplastic
Genetic Markers - drug effects
Humans
Matrix Metalloproteinase Inhibitors
Neoplasm Metastasis
Neoplasms - classification
Neoplasms - drug therapy
Neoplasms - enzymology
Prognosis
title Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A08%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gelatinases%20(MMP-2%20and%20-9)%20and%20their%20natural%20inhibitors%20as%20prognostic%20indicators%20in%20solid%20cancers&rft.jtitle=Biochimie&rft.au=Turpeenniemi-Hujanen,%20T.&rft.date=2005-03-01&rft.volume=87&rft.issue=3&rft.spage=287&rft.epage=297&rft.pages=287-297&rft.issn=0300-9084&rft.eissn=1638-6183&rft_id=info:doi/10.1016/j.biochi.2005.01.014&rft_dat=%3Cproquest_cross%3E67532149%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67532149&rft_id=info:pmid/15781315&rft_els_id=S0300908405000295&rfr_iscdi=true